OTC Switch Expert Panels Supported By AHA
This article was originally published in The Tan Sheet
The American Heart Association supports establishing expert panels that would determine what additional research is needed before a decision on a potential switch candidate can be made. The association's comments refer specifically to statin drugs.
You may also be interested in...
Differentiating the metabolic activity of red yeast rice from that of Rx statins could create a "widescale public health prevention" need for botanical supplements unencumbered by the toxicity and safety concerns associated with cholesterol-lowering drugs, according to a University of California at Los Angeles researcher.
McNeil Consumer Healthcare's Benecol spread will soon be carrying labeling stating it can reduce the risk of coronary heart disease, the company said. The new labeling follows FDA's Sept. 8 approval of McNeil's health claim petition.
Merck should conduct a head-to-head comparison study of Mevacor use in prescription and over-the-counter settings, Endocrinologic & Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for lovastatin 10 mg.